New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:07 EDTSTEMStemCells closes enrollment in Phase I/II AMD trial
StemCells announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration, or AMD, in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70% reduction in the rate of geographic atrophy as compared to the control eye and a 65% reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company's proprietary HuCNS-SC human neural stem cells. In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC as a treatment for dry AMD. Final results from this landmark study are expected to be released mid-2015.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
13:44 EDTSTEMStemCells says patent infringement case against Neuralstem dismissed by court
Subscribe for More Information
07:49 EDTSTEMNeuralstem awarded favorable court ruling in StemCell patent litigation
Subscribe for More Information
July 20, 2015
08:12 EDTSTEMStemCells transplants first patient in clinical trial for macular degeneration
StemCells announced that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The Phase II trial is designed to evaluate both the safety and efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of geographic atrophy, the most advanced form of dry age-related macular degeneration
07:33 EDTSTEMInternational AIDS Society to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use